Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve <i>Egfr</i>-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment

Immune checkpoint inhibitors (ICIs) show limited efficacy in epidermal growth factor receptor (<i>EGFR</i>)-mutant lung adenocarcinoma due to its non-inflamed tumor microenvironment (TME). While quadruple therapy combining chemotherapy, anti-programmed death-ligand 1 (PD-L1), and anti-vascular endot...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Atsuko Hirabae, Tadahiro Kuribayashi, Shuta Tomida, Sachi Okawa, Takamasa Nakasuka, Kazuya Nishii, Jun Nishimura, Go Makimoto, Kiichiro Ninomiya, Hisao Higo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masamichi Sugimoto, Yosuke Togashi, Yoshinobu Maeda, Katsuyuki Kiura, Kadoaki Ohashi
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2026-05-01
Rangatū:	Current Oncology
Ngā marau:	EGFR mutation non-small cell lung cancer syngeneic mouse model antitumor immunity non-inflamed tumor VEGF
Urunga tuihono:	https://www.mdpi.com/1718-7729/33/6/315
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve <i>Egfr</i>-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment

Ngā tūemi rite